CoChat
Sign Up
Cited by 102Cancer Immunotherapy and BiomarkersEpigenetics and DNA MethylationImmunotherapy and Immune Responses

The DOI matches its Crossref record; 145 of the 152 references it cites were found in a registry or an index.

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

Sigalotti, Luca, Fratta, Elisabetta, Coral, Sandra, Maio, Michele·2014·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2013.12.015
Open this paper in CoChat — free account

Abstract

Continuously improving knowledge of the fine mechanisms regulating cross-talk between immune cells, and of their multi-faceted interactions with cancer cells, has prompted the development of several novel immunotherapeutic strategies for cancer treatment. Among these, modulation of the host's immune system by targeting immunological synapses has shown notable clinical efficacy in different tumor types. Despite this, objective clinical responses and, more importantly, long-term survival are achieved only by a fraction of patients; therefore, identification of the mechanism(s) responsible for the differential effectiveness of immune checkpoint blockade in specific patient populations is an area of intense investigation. Neoplastic cells can activate multiple mechanisms to escape from immune control; among these, epigenetic reprogramming is emerging as a key player. Selected tumor-associated antigens, Human Leukocyte Antigens, and accessory/co-stimulatory molecules required for efficient recognition of neoplastic cells by the immune system have been shown to be epigenetically silenced or down-regulated in cancer. Consistent with the inherent reversibility of epigenetic silencing, "epigenetic" drugs, such as inhibitors of DNA methyltransferases and of histone deacetylases, can restore the functional expression of these down-regulated molecules, thus improving the recognition of cancer cells by both the innate and adaptive immune responses. This review focuses on the immunomodulatory activity of epigenetic drugs and on their proposed clinical use in novel combined chemo-immunotherapeutic regimens for the treatment of solid tumors.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.015

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 152 references

7 of the 152 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 101–102 of 102

Related

See all

Metadata

Authors
Sigalotti, L., Fratta, E., Coral, S., & Maio, M.
Affiliations
  • Centro di Riferimento Oncologico (IT)
  • University of Siena (IT)
Corresponding author
Maio, Michele
ORCID
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2014-06
Volume
142
Issue
3
Pages
339-350
ISSN
0163-7258 (ISSN-L)
DOI
10.1016/j.pharmthera.2013.12.015
OpenAlex
W2019173523
Cited by
102
References
152
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 11 · 2022: 5 · 2021: 14 · 2020: 6 · 2019: 12 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 7 · 2014: 6
FWCI
1.25
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
epigenetic drugs, immunomodulation, solid tumors, hypomethylating agents, histone deacetylase inhibitors, epigenetic silencing, immune checkpoint blockade, tumor immune evasion, tumor-associated antigens, costimulatory molecules, immunological synapse, cancer immunotherapy
MeSH terms
Animals, Humans, Immunologic Factors, Immunotherapy, Neoplasms, RNA Editing, Antigen Presentation, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review